SANTA CLARA, Calif., Oct. 23, 2006
Agilent Technologies Inc. (NYSE: A) announced today that the National Cancer Institute (NCI) has purchased a full site license for a wide range of Agilent bioinformatics solutions.
Under the agreement, the NCI is making the following solutions available to its intramural program researchers: Agilent GeneSpring GX for gene expression, Agilent CGH Analytics for comparative genomic hybridization (CGH) studies, Agilent Chip Analytics to analyze chromatin immunoprecipitation-on-chip data (ChIP-on-chip), and GeneSpring GT for genotyping and SNP analysis.
The license, arranged under the auspices of the NCI's Office of Science and Technology Partnerships, will enable standardization of bioinformatics platforms so that users communicate using the same terms and share comparable training and support.
"We're proud of our close working relationship with the NCI," said Agilent's Jordan Stockton, gene expression marketing manager, "especially in helping their researchers employ such emerging applications as aCGH and ChIP-on-chip in conjunction with gene expression to accelerate the search for ways of controlling cancer."
Agilent GeneSpring GX 7.3, the leading desktop gene-expression analysis solution, is designed to help researchers to identify targets quickly and reliably. Statistically meaningful results provide the ability to predict clinical outcomes and to characterize novel expression patterns.
Agilent CGH Analytics 3.4 lets researchers visually explore, detect and analyze aberration patterns from multiple CGH microarray profiles. Agilent ChIP Analytics 1.2 lets users visually explore and analyze data from Agilent ChIP-on-chip microarrays.
Agilent GeneSpring GT 2.0 is a desktop analysis workbench for analyzing high-volume, high-density genotyping data. A comprehensive set of linkage and association algorithms allows researchers to discover relationships between genotypes and phenotypes. Designed for biologists and statisticians, GeneSpring GT enables analysis and visualization of hundreds of thousands of variation measurements simultaneously, for rapid localization of disease or phenotype markers.
For complete details about Agilent's bioinformatics solutions, visit www.chem.agilent.com.
About the Technology
Oligonucleotide microarrays comprise short sequences of nucleotides, often used as probes for detecting complementary DNA or RNA. Array CGH technology provides a way of studying chromosomal aberrations, including copy number changes and rearrangements, across the entire genome simultaneously. Ultimately, this information can be used to determine gene activity or to pinpoint chromosomal abnormalities such as gains or losses associated with disease states.
About Agilent in Genomics
Agilent is a leading worldwide provider of microarray-based, genomics research solutions. Agilent's end-to-end solution includes reagents for sample preparation and microarray processing; hardware for sample QC and high-throughput microarray scanning; 60-mer oligo microarrays on industry-standard 1" x 3" glass slides for gene expression; comparative genomic hybridization and chromatin immunoprecipitation applications; custom microarray design services; and industry-leading GeneSpring.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 20,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.1 billion in fiscal 2005. Information about Agilent is available on the Web at www.agilent.com.
# # #
Contact:
John Watson
+1 408 553 7205
j_watson@agilent.com